Is pazopanib/pazopanib a targeted drug?

Pazopanib is a targeted therapy approved by the U.S. Food and Drug Administration (FDA) for the treatment of advanced renal cell carcinoma (RCC) and soft tissue sarcoma (STS). It belongs to the tyrosine kinase inhibitor (TKI) class of drugs and mainly acts on multiple targets such as vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR) and stem cell factor receptor (c-KIT). These receptors play a key role in tumor angiogenesis and growth. Therefore, pazopanib can effectively reduce the formation of tumor blood vessels by inhibiting these signaling pathways, thereby inhibiting tumor growth and spread.

Unlike traditional chemotherapy drugs, targeted drugs can specifically act on molecular pathways related to tumor cells and reduce damage to normal cells, thus reducing the side effects of treatment to a certain extent. As a targeted drug, pazopanib is commonly used in patients with unresectable advanced or metastatic renal cancer, especially in patients who have not received previous treatment or who have failed cytokine therapy. Additionally, it is used to treat certain types of advanced soft tissue sarcomas, particularly in patients who have previously received chemotherapy.

Although pazopanib is an effective targeted drug, it may also cause certain side effects, such as hypertension, abnormal liver function, gastrointestinal discomfort, fatigue, hand-foot syndrome, etc. Therefore, it is necessary to regularly monitor liver function and blood pressure during use, and adjust the dose or take corresponding supportive treatment measures according to the patient's specific situation.

In summary, pazopanib is a typical targeted therapy drug that controls cancer progression by inhibiting specific tumor growth signaling pathways and plays an important role in the treatment of advanced renal cancer and soft tissue sarcoma. For patients with indications, pazopanib provides a relatively effective treatment option, but physician guidance needs to be strictly followed during use to ensure the safety and effectiveness of the treatment.

Reference materials:https://www.votrient.com/